Cargando…

New anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures

BACKGROUND: There is little data available on the role of new anti-reflux plastic stents (ARPSs). AIM: To compare the use of ARPSs with that of traditional plastic stents (TPSs) for patients with biliary strictures. METHODS: Consecutive patients with biliary strictures who underwent first endoscopic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Xiang-Lei, Ye, Lian-Song, Zeng, Xian-Hui, Tan, Qing-Hua, Mou, Yi, Liu, Wei, Wu, Chun-Cheng, Yang, Hang, Hu, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326253/
https://www.ncbi.nlm.nih.gov/pubmed/34366630
http://dx.doi.org/10.3748/wjg.v27.i28.4697
_version_ 1783731747734683648
author Yuan, Xiang-Lei
Ye, Lian-Song
Zeng, Xian-Hui
Tan, Qing-Hua
Mou, Yi
Liu, Wei
Wu, Chun-Cheng
Yang, Hang
Hu, Bing
author_facet Yuan, Xiang-Lei
Ye, Lian-Song
Zeng, Xian-Hui
Tan, Qing-Hua
Mou, Yi
Liu, Wei
Wu, Chun-Cheng
Yang, Hang
Hu, Bing
author_sort Yuan, Xiang-Lei
collection PubMed
description BACKGROUND: There is little data available on the role of new anti-reflux plastic stents (ARPSs). AIM: To compare the use of ARPSs with that of traditional plastic stents (TPSs) for patients with biliary strictures. METHODS: Consecutive patients with biliary strictures who underwent first endoscopic biliary stenting between February 2016 and May 2019 were included. The onset of stent-related cholangitis, stent patency, clinical success, and other adverse events were evaluated. RESULTS: Sixty-seven patients in the ARPS group and 66 patients in the TPS group were included in the final analyses. Fewer patients experienced stent-related cholangitis in the ARPS group than that in the TPS group (8 patients vs 18 patients; P = 0.030). The median time till the onset of first stent-related cholangitis was later in the ARPS group than that in the TPS group (128.5 d vs 76 d; P = 0.039). The cumulative median stent patency in the ARPS group was 185 d, which was significantly longer than that in the TPS group (133 d; P = 0.001). The clinical success rates and other adverse events did not significantly differ between both groups. CONCLUSION: Placement of new ARPS might be a safe and effective optional therapeutic strategy to reduce the risk of stent-related cholangitis and prolong stent patency.
format Online
Article
Text
id pubmed-8326253
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-83262532021-08-06 New anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures Yuan, Xiang-Lei Ye, Lian-Song Zeng, Xian-Hui Tan, Qing-Hua Mou, Yi Liu, Wei Wu, Chun-Cheng Yang, Hang Hu, Bing World J Gastroenterol Retrospective Study BACKGROUND: There is little data available on the role of new anti-reflux plastic stents (ARPSs). AIM: To compare the use of ARPSs with that of traditional plastic stents (TPSs) for patients with biliary strictures. METHODS: Consecutive patients with biliary strictures who underwent first endoscopic biliary stenting between February 2016 and May 2019 were included. The onset of stent-related cholangitis, stent patency, clinical success, and other adverse events were evaluated. RESULTS: Sixty-seven patients in the ARPS group and 66 patients in the TPS group were included in the final analyses. Fewer patients experienced stent-related cholangitis in the ARPS group than that in the TPS group (8 patients vs 18 patients; P = 0.030). The median time till the onset of first stent-related cholangitis was later in the ARPS group than that in the TPS group (128.5 d vs 76 d; P = 0.039). The cumulative median stent patency in the ARPS group was 185 d, which was significantly longer than that in the TPS group (133 d; P = 0.001). The clinical success rates and other adverse events did not significantly differ between both groups. CONCLUSION: Placement of new ARPS might be a safe and effective optional therapeutic strategy to reduce the risk of stent-related cholangitis and prolong stent patency. Baishideng Publishing Group Inc 2021-07-28 2021-07-28 /pmc/articles/PMC8326253/ /pubmed/34366630 http://dx.doi.org/10.3748/wjg.v27.i28.4697 Text en ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Retrospective Study
Yuan, Xiang-Lei
Ye, Lian-Song
Zeng, Xian-Hui
Tan, Qing-Hua
Mou, Yi
Liu, Wei
Wu, Chun-Cheng
Yang, Hang
Hu, Bing
New anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures
title New anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures
title_full New anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures
title_fullStr New anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures
title_full_unstemmed New anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures
title_short New anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures
title_sort new anti-reflux plastic stent to reduce the risk of stent-related cholangitis in the treatment of biliary strictures
topic Retrospective Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326253/
https://www.ncbi.nlm.nih.gov/pubmed/34366630
http://dx.doi.org/10.3748/wjg.v27.i28.4697
work_keys_str_mv AT yuanxianglei newantirefluxplasticstenttoreducetheriskofstentrelatedcholangitisinthetreatmentofbiliarystrictures
AT yeliansong newantirefluxplasticstenttoreducetheriskofstentrelatedcholangitisinthetreatmentofbiliarystrictures
AT zengxianhui newantirefluxplasticstenttoreducetheriskofstentrelatedcholangitisinthetreatmentofbiliarystrictures
AT tanqinghua newantirefluxplasticstenttoreducetheriskofstentrelatedcholangitisinthetreatmentofbiliarystrictures
AT mouyi newantirefluxplasticstenttoreducetheriskofstentrelatedcholangitisinthetreatmentofbiliarystrictures
AT liuwei newantirefluxplasticstenttoreducetheriskofstentrelatedcholangitisinthetreatmentofbiliarystrictures
AT wuchuncheng newantirefluxplasticstenttoreducetheriskofstentrelatedcholangitisinthetreatmentofbiliarystrictures
AT yanghang newantirefluxplasticstenttoreducetheriskofstentrelatedcholangitisinthetreatmentofbiliarystrictures
AT hubing newantirefluxplasticstenttoreducetheriskofstentrelatedcholangitisinthetreatmentofbiliarystrictures